Abstract | OBJECTIVE: The presence of plasmacytomas (Ps) in patients with multiple myeloma (MM) is associated with a poor outcome, both in patients treated conventionally and in patients treated with novel agents. Two types of plasmacytomas have being recognized: paraskeletal plasmacytomas (PPs) and extramedullary plasmacytomas (EMPs), being the incidence of EMPs lower but with worse prognosis. Our aim has been to analyze the efficacy of the pomalidomide- dexamethasone combination in this patient profile. METHOD: RESULTS: While 34% of the patients achieved a paraprotein response, only two patients with PPs (9%) responded (RC and PR). There were no responses among patients with EMPs. The median progression-free survival from the start of treatment with pomalidomide/ dexamethasone was only 1.7 months and the median overall survival of 4.5 months. CONCLUSION:
|
Authors | Raquel Jiménez-Segura, Miquel Granell, Mercè Gironella, Eugenia Abella, Antoni García-Guiñón, Albert Oriol, Elena Cabezudo, Victoria Clapés, Joan Alfons Soler, Lourdes Escoda, Jordi López-Pardo, Carlos Fernández de Larrea, Maria Teresa Cibeira, Natalia Tovar, Ignacio Isola, Joan Bladé, Laura Rosiñol, GEMMAC (Grup per l l'estudi del mieloma mútiple i l'amiloïdosi de Catalunya) |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 102
Issue 5
Pg. 389-394
(May 2019)
ISSN: 1600-0609 [Electronic] England |
PMID | 30719772
(Publication Type: Journal Article)
|
Copyright | © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Thalidomide
- Dexamethasone
- pomalidomide
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Dexamethasone
(administration & dosage)
- Drug Resistance, Neoplasm
- Female
- Humans
- Male
- Middle Aged
- Multimodal Imaging
- Multiple Myeloma
(complications, diagnosis)
- Neoplasm Recurrence, Local
- Plasmacytoma
(complications, diagnosis, drug therapy)
- Soft Tissue Neoplasms
(complications, diagnosis, drug therapy)
- Thalidomide
(administration & dosage, analogs & derivatives)
|